Valiant Thoracic Stent Graft System


Company Medtronic, Inc.
Phone (888) 283-7868
Web www.medtronicendovascular.com
Key Features

  • Proximal 8-Peak FreeFlo configuration
  • Hydrophilic coating on delivery system
  • Tip capture for controlled deployment

The Valiant thoracic stent graft with the Captivia delivery system (Medtronic, Inc., Minneapolis, MN) is indicated for endovascular repair of fusiform and saccular aneurysms and penetrating ulcers of the descending thoracic aorta in patients having appropriate anatomy, including: iliac or femoral access vessel morphology that is compatible with vascular access techniques, devices, and/or accessories; nonaneurysmal aortic diameter in the range of 18–42 mm; and nonaneurysmal aortic proximal and distal neck lengths ≥ 20 mm.

The Valiant thoracic stent graft system delivered excellent clinical results through 1 year of patient follow-up in Medtronic's VALOR II pivotal study, a prospective, single-arm study of 160 patients at 24 US medical centers. Designed to evaluate the safety and effectiveness of the Valiant system for TEVAR in the descending thoracic aorta, VALOR II was led by Principal Investigator Ronald Fairman, MD, the Clyde F. Barker–William Maul Measey Professor of Surgery at the Hospital of the University of Pennsylvania. “The VALOR II 12-month results demonstrate that the Medtronic Valiant stent graft is a safe and effective treatment for patients with descending TAAs of degenerative etiology. Through 12 months, there were no cases of rupture or conversion to open surgery. Overall, treatment results were quite promising,” Dr. Fairman stated.


DuraFlow 2 Chronic Hemodialysis Catheter


Company AngioDynamics, Inc.
Phone (518) 798-1215
Web www.angiodynamics.com
Key Features

  • Convenient, redesigned kit to facilitate inventory control
  • Only 48-cm chronic dialysis catheter available
  • Thermoplastic polyurethane luer for increased durability
  • VP kits provide ideal fit with many currently available medical supply stations

AngioDynamics, Inc. (Latham, NY) announced the US launch of the next-generation DuraFlow 2 chronic hemodialysis catheter and the upcoming launch of the DuraFlow 2 VascPak (VP) kit. Along with the DuraMax chronic hemodialysis catheter, AngioDynamics offers the only 48-cm chronic dialysis catheters on the market, allowing for femoral catheter placements in patients of varying sizes. The DuraFlow 2 catheter continues to provide optimal ease of insertion and sustained high flow rates. A new tough, rigid thermoplastic polyurethane luer increases durability, allowing for more secure fastening to dialysis machines, the company stated.

The VP kit, set for launch in the fiscal 2012 fourth quarter, is designed to meet the needs of many outpatient vascular access centers. Additionally, tray sizes for both the VP and basic kits have been reduced by approximately 30%, providing an ideal fit with popular automated medical supply stations and easier handling and storage.


TruePath CTO Device


Company Boston Scientific Corporation
Phone (888) 272-1001
Web www.bostonscientific.com/ peripheral-interventions
Key Features

  • Diamond-coated tip
  • 0.018-inch wire
  • Longest crossing device (165 cm)
  • 1:1 torque response
  • No capital equipment required

Boston Scientific Corporation (Natick, MA) has announced the United States launch of the TruePath CTO device, which is designed to facilitate the crossing of chronic total occlusions (CTOs) within the peripheral vasculature. The company expects to launch the product in Europe and other international markets in the first half of 2012.

The TruePath CTO device features a rotating diamond-coated tip that is designed to break through occluded peripheral arteries and facilitate the placement of conventional guidewires for treatment of peripheral lesions. The ultra-low 0.018-inch profile is engineered for optimal crossing. Once positioned, the distal tip rotates at 13,000 rpm to facilitate drilling through calcified lesions and other fibrous blockages. The TruePath device requires no capital equipment and is available with an optional extension wire to facilitate catheter exchange and increase the working length beyond 300 cm.

“The TruePath device is an exciting new technology that allows me to effectively penetrate difficult blockages, allowing access to untreated lesions and helping to improve overall patient outcomes,” said J. A. Mustapha, MD.


Arrow NextStep Antegrade Dialysis Catheter


Company Teleflex Incorporated
Phone (610) 948-2836
Web www.teleflex.com
Key Features

  • Openings are reversed to take better advantage of blood flow dynamics within the heart
  • Distal tips of both lumens are significantly separated to help enhance flow and minimize recirculation
  • Combines a step-tip catheter's ease of insertion with a split-tip catheter's sustained high flow

Teleflex Incorporated (Limerick, PA) has announced that it has expanded its interventional access portfolio with the Arrow NextStep antegrade catheter, which is now available for sale in the United States. The Arrow NextStep antegrade catheter is a chronic hemodialysis catheter that combines a step-tip catheter's ease of insertion with a split-tip catheter's sustained high flow. Its unique tip is designed for smooth, over-the-wire transitions during catheter insertions and exchanges, the company stated.

To reduce recirculation and deliver high flow, the Arrow NextStep antegrade catheter's tip provides two unique, complementary features: (1) the openings are reversed to take better advantage of blood flow dynamics within the heart; and (2) the distal tips of both lumens are significantly separated to help enhance flow and minimize recirculation.

The Arrow chronic hemodialysis catheter portfolio offers both split-tip and step-tip catheters for both retrograde and antegrade insertion techniques. The Arrow NextStep product family consists of step-tip catheters that can be tunneled using the retrograde or antegrade technique.